6	IP.E	40.0	\mathbf{X}
$\left(\begin{array}{c} \\ \end{array} \right)$	AUG 1	o ²⁰⁰⁹	HICK T
Ĺ	A		
	ENT 81	RADEN	nnlic

-

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

۰.

8-5-9

TRA	Applicant:	Ashley, Robert		Examiner:	Tran, Susan T.
	Serial No.:	11/876,478		Group Art Unit:	1615
	Confirmation No:	6286		Docket:	512-53 DIV/CON
	Filed:	October 22, 2007		Dated:	August 5, 2009
	For: .	METHODS OF TREATING ACNE		•.	
Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450		I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on August 5, 2009			

AMENDMENT

Signed:

Sir:

Δ

In the response to the February 5, 2009 Office Action, applicants file herewith the instant Amendment.

Amendments to the Specification: None.

Amendments to Claims:

Begin on page 2 of this paper.

Remarks:

R

Μ

Begin on page 19 of this paper.

Find authenticated court documents without watermarks at docketalarm.com.

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound, wherein said tetracycline compound is a non-antibiotic tetracycline compound.

2. (previously presented) A method according to Claim 1, wherein said acne is acne vulgaris, cystic acne, acne atrophica, bromide acne, chlorine acne, acne conglobata, acne cosmetica, acne detergicans, epidemic acne, acne estivalis, acne fulminans, halogen acne, acne indurata, iodide acne, acne keloid, acne mechanica, acne papulosa, pomade acne, premenstral acne, acne pustulosa, acne rosacea, acne scorbutica, acne scrofulosorum, acne urticata, acne varioliformis, acne venenata, propionic acne, acne excoriee, gram negative acne, steroid acne, or nodulocystic acne.

Claims 3-23 (canceled).

24. (currently amended) A method according to <u>Claim 1 Claim 23</u>, wherein said non-antibiotic tetracycline compound is:

4-de(dimethylamino)tetracycline (CMT-1), tetracyclinonitrile (CMT-2),

6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3),

4-de(dimethylamino)-7-chlorotetracycline (CMT-4),

tetracycline pyrazole (CMT-5)


4-hydroxy-4-de(dimethylamino)tetracycline (CMT-6),

4-de(dimethylamino)-12α-deoxytetracycline (CMT-7),

6-α-deoxy-5-hydroxy-4-de(dimethylamino)tetracycline (CMT-8),

4-de(dimethylamino)-12α-deoxyanhydrotetracycline (CMT-9), or
4-de(dimethylamino)minocycline (CMT-10),
<u>or pharmaceutically acceptable salts thereof.</u>

25. (currently amended) A method according to <u>Claim 1 Claim 23</u>, wherein the nonantibiotic tetracycline compound is selected from the group consisting of:



Applicant(s): Robert A. Ashley Serial No.: 11/876,478 Filed: October 22, 2007 Page 4 of 34

wherein:

R7 is selected from the group consisting of hydrogen, amino, nitro, mono(lower alkyl) amino, halogen, di(lower alkyl)amino, ethoxythiocarbonylthio, azido, acylamino, diazonium, cyano, and hydroxyl;

R6-a is selected from the group consisting of hydrogen and methyl;

R6 and R5 are selected from the group consisting of hydrogen and hydroxyl;

R8 is selected from the group consisting of hydrogen and halogen;

R9 is selected from the group consisting of hydrogen, amino, azido, nitro, acylamino, hydroxy, ethoxythiocarbonylthio, mono(lower alkyl) amino, halogen, diazonium, di(lower alkyl)amino and RCH(NH₂)CO;

R is hydrogen or lower alkyl; and

pharmaceutically acceptable salts thereof; with the following provisos:

when either R7 and R9 are hydrogen then R8 must be halogen; and

when R6-a, R6, R5 and R9 are all hydrogen and R7 is hydrogen, amino, nitro, halogen,

dimethylamino or diethylamino, then R8 must be halogen; and

when R6-a is methyl, R6 and R9 are both hydrogen, R5 is hydroxyl, and R7 is hydrogen, amino, nitro, halogen or diethylamino, then R8 is halogen; and


when R6-a is methyl, R6 is hydroxyl, R5, R7 and R9 are all hydrogen, then R8 must be halogen; and

when R6-a, R6 and R5 are all hydrogen, R9 is methylamino and R7 is dimethylamino, then R8 must be halogen; and

when R6-a is methyl, R6 is hydrogen, R5 is hydroxyl, R9 is methylamino and R7 is dimethylamino, then R8 must be halogen; and

when R6-a is methyl, R6, R5 and R9 are all hydrogen and R7 is cyano, then R8 must be halogen, and pharmaceutically acceptable salts thereof.

26. (currently amended) A method according to <u>Claim 1 Claim 23</u>, wherein the nonantibiotic tetracycline compound is selected from the group consisting of:



wherein:

R7 is selected from the group consisting of hydrogen, amino, nitro, mono(lower alkyl) amino, halogen, and di(lower alkyl)amino, ethoxythiocarbonylthio, azido, acylamino, diazonium, cyano, and hydroxyl;

Structure J

R6-a is selected from the group consisting of hydrogen and methyl;

R6 and R5 are selected from the group consisting of hydrogen and hydroxyl;

R4 is selected from the group consisting of NOH, N-NH-A, and NH-A,

where A is a lower alkyl group;

Structure I

R8 is selected from the group consisting of hydrogen and halogen;

R9 is selected from the group consisting of hydrogen, amino, azido, nitro, acylamino, hydroxy, ethoxythiocarbonylthio, mono(lower alkyl) amino, halogen, di(lower alkyl)amino and RCH(NH₂)CO;

R is hydrogen or lower alkyl; and

pharmaceutically acceptable salts thereof; with the following provisos:

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.